In contrast, Ezh2 null tumors were more metastatic and higher grade. Despite the fact that EZH2 inhibitors may drive more aggressive phenotypes in cancer, there still may be clinical utility for EZH2 inhibitors due to effects on the tumor microenvironment, and the ability to drive additional therapeutic vulnerabilities of tumor cells. This evidence concerns the gene EZH2 and cancer.